Bioanalysis, Drug Metabolism and New Drug Discovery

在患有难治性双相抑郁(BP)和被诊断为复杂区域疼痛综合征(CRPS)的无反应性慢性疼痛的患者中，氯胺酮的治疗有反应。CRPS患者接受了为期5天的药物输注，75%的患者疼痛缓解，67%的BP在单次服药后有反应。这项正在进行的研究的目的是确定一些患者有反应而另一些患者没有反应的原因，能够在治疗开始前确定应答者，并进行个体化治疗以提高应答率。数据表明，氯胺酮的治疗活性部分归因于(2R，6R)-羟基去甲氯胺酮和去甲氧氯胺酮，并对其药理活性进行了研究。此外，代谢组学研究已经确定，BP患者对氯胺酮治疗的反应和无反应与线粒体功能有关。这一关系正在调查中。

In patients suffering from treatment-resistant bipolar depression (BP) and with unresponsive chronic pain that is diagnosed as Complex Regional Pain Syndrome (CRPS)have responded to treatment with ketamine. The CRPS patients were treated with a five-day infusion of the drug produced pain relief in 75% of the patients and 67% of the BP responded after a single dose. The objective of the ongoing study is to identify the reasons why some patients respond and other do not, to be able to identify the responders before treatment begins and to individualize treatment to increase response. The data indicates that the therapeutic activity of ketamine is due, in part, to (2R,6R)-hydroxynorketamine and dehydronorketamine and the pharmacological activities of the compounds have been investigated. In addition, metabolomic studies have determined that response and non-response to treatment with ketamine in BP patients is related to mitochodrial function. This relationship is under investigation.